Author Correction: Generation of a CRISPR activation mouse that enables modelling of aggressive lymphoma and interrogation of venetoclax resistance

Nat Commun. 2022 Aug 25;13(1):5007. doi: 10.1038/s41467-022-32817-9.

Yexuan Deng^#^{1

2}, Sarah T Diepstraten^#^{2

3}, Margaret A Potts^{2

3}, Göknur Giner^{2

3}, Stephanie Trezise^{2

3}, Ashley P Ng^{2

3}, Gerry Healey^{2

3}, Serena R Kane^{2

3}, Amali Cooray^{2

3}, Kira Behrens^{2

3}, Amy Heidersbach⁴, Andrew J Kueh^{2

3}, Martin Pal^{2

3

5}, Stephen Wilcox^{2

3}, Lin Tai², Warren S Alexander^{2

3}, Jane E Visvader^{2

3}, Stephen L Nutt^{2

3}, Andreas Strasser^{2

3}, Benjamin Haley⁴, Quan Zhao¹, Gemma L Kelly^{2

3}, Marco J Herold^{6

7}

¹ The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hepatobiliary Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, School of Life Sciences, Nanjing University, Nanjing, Jiangsu, China.
² The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
³ Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia.
⁴ Department of Molecular Biology, Genentech, Inc., South San Francisco, CA, USA.
⁵ School of Dentistry and Medical Sciences, Charles Sturt University, Wagga Wagga, NSW, Australia.
⁶ The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia. herold@wehi.edu.au.
⁷ Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia. herold@wehi.edu.au.

^# Contributed equally.

No abstract available

Publication types